Search Result

All Related Services Other Content

ASD Series
Characterization and Evaluation of Amorphous Solid Dispersion-Part 2 Amorphous solid dispersion (ASD) offers enhanced solubility over crystalline forms due to its elevated Gibbs free energy. Additionally, ASD is capable of maintaining high levels of supersaturation in ...
BioTechX USA Crystal Pharmatech is heading to BioTechX USA 2025!We're excited to join our partner biosimulytics at Booth S5 on September 16-17 in Philadelphia.Come meet our Co-founder & CBO, Dr. Robert Wen...
Solid-State NMR Analysis Nuclear Magnetic Resonance (NMR) Spectroscopy is a ubiquitous analytical technique utilized across a wide range of disciplines.
Crystal Pharmatech Recognized as "Best Partner" by Allorion Therapeutics for Excellent Services Suzhou, China - July 7, 2023 - Crystal Pharmatech, a leading pharmaceutical technology company, has received dual recognition from its esteemed partner, Allorion Therapeutics (Boston, US / Guangzhou, ...
Formulation and Analytical Development Instead of one-size-fits-all platforms, Crystal Pharmtech applies a "First-Time-Right" strategy for formulation development to accelerate your molecule to First in Human (FIH) studies and onward to commercialization in a cost-effective and time-saving way.
Animal Dosing Vehicle Selection Choosing an optimal vehicle for animal PK and Tox studies requires multidisciplinary skillsets and a sound understanding of the physicochemical properties of your compound. Controlling solid and solut...
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (I) - Hot Melt Extrusion Hot-melt extrusion (HME) is recognized as an optimal and efficient technique for manufacturing amorphous solid dispersions, characterized by its continuous processing, increased production efficiency,...
Biologics
Overcoming Bioavailability Barrier to Deliver Protein Degraders Speaker: Dr. Chong-Hui Gu, Head of CMC and QA, Foghorn Therapeutics

Protein degraders offer a new opportunity to address targets that were previously undruggable. However, oral bioavailability issues have limited the use of this modality. This talk will address the factors that limit oral absorption and approaches to overcome those issues. This talk will also overview other delivery options to deliver protein degraders such as long acting injectable formulations.